



Ontario Health
Cancer Care Ontario

Symptom Management Algorithm

**Oral Care for
Hematopoietic Stem
Cell Transplantation
(HSCT)**

In Adults with Cancer

About This Document

The Oral Care for Hematopoietic Stem Cell Transplantation (HSCT) document provides guidance to healthcare professionals on:

- Risks of oral complications arising from HSCT
- Prevention of oral complications arising from HSCT
- Oral care strategies for patients before, during, and after HSCT
- Treatment of oral complications arising from HSCT

Risks of Oral Complications Arising from HSCT

Oral Mucositis*

Oral mucositis (OM) is an acute inflammation and/or ulceration of the oral mucosal membranes. It can cause pain and discomfort, and can interfere with eating, swallowing, and speech. Risks factors include:

- Frequency and severity in blood or bone marrow transplantation patients related to:
 - Intensity of conditioning regime
 - Use of prophylactic methotrexate to prevent Graft versus Host Disease

Signs and symptoms of OM include:

- Erythema
- Bleeding
- Altered Taste
- Oral pain
- Odynophagia (painful swallowing)

Infections***

HSCT patients are at high-risk for infectious diseases caused by fungi, bacteria, and viruses. Risk factors include:

- Neutropenia
- Poor oral hygiene
- Dry mouth
- Malnutrition
- Dehydration
- Denture use
- Antibiotic course
- Inhaled corticosteroids
- Tobacco use
- Previous history of herpes labialis, oral herpes simplex virus, or herpes zoster

Signs and symptoms of infections include:

- Swelling
- Pus
- Redness
- Fever
- Fetid odor
- Prodrome (numbness, tingling, and/or burning prior to onset of lesions)

Graft versus Host Disease

Graft versus Host Disease (GvHD) is a condition that occurs when donated stem cells or bone marrow see the healthy tissues in the patient's body as foreign, and attack them. Risk factors include:

- Human leukocyte antigen disparity
- Gender mismatch
- Donor type
- Stem cell source
- Conditioning regimen
- GvHD prophylaxis regimen

Signs and symptoms of GvHD include:

- Dry mouth
- Mouth ulcers
- Infections
- Gingival overgrowth
- Tobacco intervention
- Trismus**




Figure 1: Oral graft versus host disease



Figure 2: Chronic graft versus host disease



Figure 3: Necrosis of gingivae Neutropenia



Figure 3: Leukemic infiltration of the gingiva

*See the Oral Mucositis algorithm for more information

**See the Trismus algorithm for more information

***See the Oral Infections algorithm for more information

Prevention of Oral Complications Arising from HSCT

<p>Before HSCT</p>	<ul style="list-style-type: none"> • Referral to dentist with expertise in HSCT dental management. Oral dental examination inclusive of: <ul style="list-style-type: none"> ○ Full mouth series x-rays ○ Full periodontal assessment ○ Sialometry, range of motion ○ Elimination foci of infection or trauma such as extractions, ill-fitting dentures, orthodontic brackets, broken or lost fillings/teeth, mobile teeth • All elective dental care should not be carried out for 12 months after HSCT
<p>During HSCT Chemotherapy</p>	<p><u>Oral Hygiene</u></p> <ul style="list-style-type: none"> • Encourage brushing and flossing two times a day with prescriptive fluoride and calcium phosphate toothpastes • Review dry mouth (xerostomia[*]) care and intensified oral care with patient • Prophylaxis as per institution protocol for candidiasis and viral reactivation <p><u>Pain Control</u></p> <ul style="list-style-type: none"> • See Table 1 for medications to manage pain (page 6) • Systemic analgesia (i.e. oral, parenteral, or transdermal opioids) may be required for patients with mucositis <p><u>Oral Mucositis^{**}</u></p> <ul style="list-style-type: none"> • Starting 5 minutes before chemotherapy (CT) administration, swish ice chips in mouth. Continue for duration of CT infusion, and for 5 minutes after drug is completed • Oral cryotherapy is recommended to prevent oral mucositis in patients undergoing autologous HSCT when the conditioning includes high-dose melphalan • Patients receiving high dose CT and total body irradiation with autologous stem cell transplant, keratinocyte growth factor (palifermin) for 3 days before treatment and for 3 days after transplant • Intra-oral photobiomodulation (PBM) therapy using low level laser therapy in adults receiving HSCT conditioned with high-dose CT, with or without total body irradiation is recommended. See Table 2 for recommended PBM therapy protocols (page 6) <p><u>Graft Versus Host Disease (GvHD)</u></p> <ul style="list-style-type: none"> • Assess for symptoms of GvHD. See the GvHD risk factors (page 2) • Chronic GvHD (mucosa, salivary gland): consult with an oral medicine specialist/dentist for current treatment recommendations, and motivate patient to keep routine surveillance (risk for squamous cell carcinoma)
<p>After HSCT Chemotherapy Until First Follow-Up with Specialist Dentist</p>	<ul style="list-style-type: none"> • Prophylaxis as per institution protocol for candidiasis and viral reactivation • Consult dental specialist team for pain of dental origin • Patients should be assessed after transplant every 90 days by a trained dentist • If patient is completing an allogeneic HSCT, the patient should see a dental specialist for any dental emergencies and care. Sialometry and trismus^{***} measurements should be repeated • Elective procedures should not be carried out for 12 months after HSCT. This includes: <ul style="list-style-type: none"> ○ Denture fabrication ○ Elective restorative ○ Asymptomatic endodontic treatment ○ Extractions <p><u>Graft Versus Host Disease (GvHD)</u></p> <ul style="list-style-type: none"> • Assess for symptoms of GvHD, including: xerostomia[*], mouth ulcers, infections^{****}, gingival overgrowth, risk for oral cancer, tobacco intervention, and trismus^{***} • Chronic GvHD (mucosa, salivary gland): consult with an oral medicine specialist/dentist for current treatment recommendations, and motivate patient to keep routine surveillance (risk for squamous cell carcinoma)

*See the Xerostomia algorithm for more information

**See the Oral Mucositis algorithm for more information

***See the Trismus algorithm for more information

****See the Oral Infections algorithm for more information

Oral Care Strategies for Patients Before, During, and After HSCT

Flossing

Before HSCT	<ul style="list-style-type: none"> Floss at least once a day Patients with trismus, dysphagia, and/or dysgeusia may not be able to floss; use of interproximal brushes can replace flossing Waxed floss may be easier to use and minimize trauma to the gingivae
During HSCT Chemotherapy	<ul style="list-style-type: none"> Continue with Before HSCT plan
After HSCT Chemotherapy Until First Follow-Up with Specialist Dentist	<ul style="list-style-type: none"> Continue with Before HSCT plan

Discontinue flossing if:

- Gums bleed for longer than two minutes

Restart flossing if:

- Platelet count is $>20 \times 10^9$ cells/L, or as instructed by cancer care team

Brushing

Before HSCT	<ul style="list-style-type: none"> Use a small, ultra-soft-headed, rounded-end, bristle toothbrush (an ultrasonic toothbrush may be acceptable) Use a prescription strength fluoride toothpaste. Spit out the foam but do not rinse mouth Use a fluoridated tooth paste and re-mineralizing toothpaste containing calcium and phosphate Brush tongue gently from back to front Rinse brush after use in hot water and allow to air dry Change toothbrush when bristles are not standing up straight Brush within 30 minutes after eating and before bed. Ensure the gingival portion of the tooth and periodontal sulcus (where the tooth meets the gum) are included
During HSCT Chemotherapy	<ul style="list-style-type: none"> Continue with Before HSCT plan Encourage patient to continue brushing through treatment phase even when it causes discomfort If unable to tolerate brushing, seek assistance from nursing or dental staff If there has been an oral infection, use a new toothbrush after infection has resolved
After HSCT Chemotherapy Until First Follow-Up with Specialist Dentist	<ul style="list-style-type: none"> Continue with Before and During HSCT plan

Patients with dentures:

- It is important to leave dentures out as much as possible during transplantation phase

Rinsing

Before HSCT	<ul style="list-style-type: none"> Rinsing the oral cavity vigorously helps maintain the moisture in the mouth, removes the remaining debris and toothpaste, and reduces the accumulation of plaque and infection Use a bland rinse to increase oral clearance which may be helpful for maintaining oral hygiene and improving patient comfort. Club soda should be avoided, due to the presence of carbonic acids Following emesis, rinse with bland rinse immediately to neutralize the mouth
During HSCT Chemotherapy	<ul style="list-style-type: none"> Perform in place of brushing if patient is absolutely unable to brush Seek dental care where possible for removing plaque Rinse after meals, and 30 minutes after brushing If unable to clean using toothette, gauze or swishing (or tilting head), syringe a bland rinse into different areas of mouth
After HSCT Chemotherapy Until First Follow-Up with Specialist Dentist	<ul style="list-style-type: none"> Continue with Before and During HSCT plan

Patients with dentures:

- After removing dentures rinse mouth thoroughly with rinse solution
- Brush and rinse dentures after meals and at bedtime
- Rinse with a bland rinse before placing in mouth
- Remove from mouth nightly (at least 8 hours per 24 hours) and soak in a bland rinse

Bland rinse:

- 1 teaspoon salt, 1 teaspoon baking soda, 4 cups of water

Moisturizing the Oral Cavity

Before HSCT	<ul style="list-style-type: none"> Moisturize the mouth with water, artificial saliva products, or other water soluble lubricants for use inside the mouth Avoid glycerin or lemon-glycerin swabs as they dry the mouth and do not moisturize Apply lubricant after each cleaning, at bedtime, and as needed Water-based lubricant needs to be applied more frequently Frequent rinsing as needed with bland rinse
During HSCT Chemotherapy	<ul style="list-style-type: none"> Continue with Before HSCT plan
After HSCT Chemotherapy Until First Follow-Up with Specialist Dentist	<ul style="list-style-type: none"> Continue with Before HSCT plan Use a steam vaporizer at night May use a cool mist humidifier at night, but use should be weighed against the risk for fungal infection

Bland rinse:

- 1 teaspoon salt, 1 teaspoon baking soda, 4 cups of water

Lip Care

Before HSCT	<ul style="list-style-type: none"> To keep lips moist and to avoid chapping and cracking use water soluble lubricants, lanolin (wax-based), or oil based (mineral oil, cocoa butter) lubricants Water soluble lubricants should be used inside and outside the mouth, and may also be used with oxygen, e.g. products compounded with Glaxal base or Derma base Apply lubricant after each cleaning, at bedtime, and as needed Water-based lubricants need to be applied more frequently Patients should be encouraged not to touch any lip lesions
During HSCT Chemotherapy	<ul style="list-style-type: none"> Continue with Before HSCT plan
After HSCT Chemotherapy Until First Follow-Up with Specialist Dentist	<ul style="list-style-type: none"> Continue with Before HSCT plan, with increased frequency and intensity as needed

Avoid:

- Oil based lubricants on the inside of the mouth
- Petroleum based products

Treatment of Oral Complications Arising from HSCT

Brushing

Before, During, After HSCT	<ul style="list-style-type: none"> If bleeding occurs, encourage gentler brushing If unable to continue brushing, clean teeth with a clean, moist gauze or foam swab Consider topical anesthetics (e.g. viscous lidocaine 2%, or viscous xylocaine 2%, 2-5mL) before brushing and eating to minimize pain With continuous pain, a regularly prescribed oral analgesic allows for more thorough tooth brushing Use of a non-flavoured, non-alcoholic chlorhexidine gluconate (CHX) 0.12% rinse to aid in plaque control Discontinue use of toothpaste if it is too astringent and dip toothbrush in bland rinse
-----------------------------------	--

Discontinue brushing if:

- Gums bleed for longer than two minutes

Restart brushing if:

- Platelet count is $>20 \times 10^9$ cells/L, or as instructed by cancer care team

Lidocaine alternative:

- Dyclonine 0.5% or 1% rinse (5mL every 6 to 8 hours, swish and swallow) as needed for pain

Rinsing

Before, During, After HSCT	<ul style="list-style-type: none"> Debriding should only be done if absolutely necessary, if tissue is loose causing gagging or choking Use CHX 0.12% non-alcoholic, non-flavoured rinse at the time of admission and continued for 12 months after HSCT, if oral hygiene is impaired CHX can enhance oral dryness and staining of teeth and dorsum tongue. Some patients will develop a taste disturbance after use, and therefore rinsing after meals is recommended
-----------------------------------	---

Avoid:


- Mouthwashes with hydroalcoholic base or astringent properties

Reference Tables

Opioid Use

- The opioid crisis has devastating consequences for individuals, families, and communities across Canada. Choosing Wisely Canada has launched Opioid Wisely, a campaign that encourages thoughtful conversation between clinicians and patients to reduce harms associated with opioids
- Visit [Choosing Wisely Canada](#) for more information and best practices on administering opioids

Table 1: Medications for the Management of Pain—WHO Analgesic Ladder (Adapted from Christoforou et al. 2019¹)



Rx Step 1	Dispense	Dose and Route
Viscous lidocaine 2%	100mL	<ul style="list-style-type: none"> Swish and spit as needed, can be swallowed. Maximum of 4.5mg/kg (or 300mg per dose) and no more than 8 doses per 24-hour period
Dyclonine 0.5% or 1% rinse	250mL	<ul style="list-style-type: none"> Swish and swallow 5mL every 6 to 8 hours. Can be used in patients with allergy to amides (lidocaine)
Benzydamine 0.15% rinse	250mL	<ul style="list-style-type: none"> Rinse and gargle the mouth and throat with 15mL (1 Tbsp.) 3 to 4 times a day, beginning the day prior to starting therapy Continue use during therapy, and after discontinuing therapy until symptoms disappear Maintain mouthwash in contact with the inflamed mucosa for at least 30 seconds. Spit the solution from mouth after use. Mouthwash should be used undiluted, but if stinging occurs it may be diluted with an equal volume of lukewarm water LU Code: 240 - For the symptomatic relief of treatment induced mucositis in cancer patients
Rx Step 2	Dispense	Dose and Route
Codeine phosphate 5mg/mL syrup	168mL	<ul style="list-style-type: none"> 30mg/6mL, 4 times a day for 7 days, as needed
Tramacet (tramadol-acetaminophen) 37.5mg/325mg tablets	60 tablets	<ul style="list-style-type: none"> Take 1 to 2 tablets every 6 hours, as needed
Doxepin suspension 5mg/ml containing 0.1% alcohol and sorbitol	200mL	<ul style="list-style-type: none"> Rinse 5mL for 1 minute and then spit out. Repeat up to 6 times a day
Rx Step 3	Dispense	Dose and Route
Hydromorphone 1mg/mL liquid	60mL	<ul style="list-style-type: none"> Take 1mL every 2 hours, as needed
Topical morphine 0.2% rinse	100mL	<ul style="list-style-type: none"> Take 15mL, hold in mouth for 2 minutes and then spit, every 3 hours, as needed
Percocet (oxycodone 5mg, acetaminophen 325mg)	20 tablets	<ul style="list-style-type: none"> Take 1 tablet 4 times a day, as needed
Fentanyl Transderm Patch 12mcg/hour, 25mcg/hour, 50mcg/hour, 75mcg/hour	10 patches	<ul style="list-style-type: none"> Apply new patch every 3 days. LU Code – 201

Table 2: Intra-Oral Photobiomodulation Therapy Protocols for the Prevention of Oral Mucositis (Adapted from Zadik, 2019²)

Cancer Treatment Type	Wave-Length (nm)	Power Density (Irradiance mW/cm ²)	Time per Spot (sec)	Energy Density (Fluence J/cm ²)	Spot Size (cm ²)	# of Sites	Duration
HSCT	632.8	31.25	40	10	0.8	18	From day after cessation of conditioning, for 5 days
	650	1000 ⁺	2	2.0	0.04	54-70	From 1 st day of conditioning till day + 2 post-HSCT (for 7 to 13 days)
RT	632.8	24	125	3.0	1	12	Entire RT course
RT-CT	660	417 ⁺	10	4.2	0.24	72	Entire RT course
	660	625 ⁺	10	6.2	0.04	69	Entire RT course

⁺Potential thermal effect. The clinician is advised to pay attention to the combination of specific parameters

References

1. Christoforou, J., Karasneh, J., Manfredi, M., Dave, B., Walker, J. S., Dios, P. D., Epstein, J., Kumar, N., Glick, M., Lockhart, P. B., & Patton, L. L. (2019). World Workshop on Oral Medicine VII: Non-opioid pain management of head and neck chemo/radiation-induced mucositis: A systematic review. *Oral Diseases*, 25(S1), 182-192. <https://doi.org/10.1111/odi.13074>
2. Zadik, Y., Arany, P.R., Fregnani, E.R. et al. Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines. *Support Care Cancer* 27, 3969–3983 (2019). <https://doi.org/10.1007/s00520-019-04890-2>
3. Sambunjak D, Nickerson JW, Poklepovic T, Johnson TM, Imai P, Tugwell P, Worthington HV (2011) Flossing for the management of periodontal diseases and dental caries in adults. *Cochrane Database Syst Rev* 12, CD008829. doi:10.1002/14651858.CD008829.pub2
4. de Souza RF, de Freitas Oliveira Paranhos H, Lovato da Silva CH, Abu-Naba'a L, Fedorowicz Z, Gurgan CA (2009) Interventions for cleaning dentures in adults. *Cochrane Database Syst Rev* 4, CD007395. doi:10.1002/14651858.CD007395.pub2
5. Glennly AM, Gibson F, Auld E, Coulson S, Clarkson JE, Craig JV, Eden OB, Khalid T, Worthington HV, Pizer B (2010) The development of evidence-based guidelines on mouth care for children, teenagers and young adults treated for cancer. *Eur J Cancer* 46(8):1399–1412. doi:10.1016/j.ejca.2010.01.023
6. Elad S, Cheng KKF, Lalla RV, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. *Cancer*. 2020 Oct;126(19):4423-4431. DOI: 10.1002/cncr.33100.
7. Funk CS, Warmling CM, Baldisserotto J. A randomized clinical trial to evaluate the impact of a dental care program in the quality of life of head and neck cancer patients. *Clin Oral Investig*. 2014 May;18(4):1213-1219. doi: 10.1007/s00784-013-1068-2. Epub 2013 Aug 30. PMID: 23989505.
8. Elad, S., Raber-Durlacher, J.E., Brennan, M.T. et al. Basic oral care for hematology–oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). *Support Care Cancer* 23, 223–236 (2015). <https://doi.org/10.1007/s00520-014-2378-x>
9. Hong, C. H., Hu, S., Haverman, T., Stokman, M., Napeñas, J. J., Bos-den Braber, J., ... & Saunders, D. P. (2018). A systematic review of dental disease management in cancer patients. *Supportive Care in Cancer*, 26(1), 155-174.
10. Lalla, R.V., Latortue, M.C., Hong, C.H. et al. A systematic review of oral fungal infections in patients receiving cancer therapy. *Support Care Cancer* 18, 985–992 (2010). <https://doi.org/10.1007/s00520-010-0892-z>
11. Elad, S., Jensen, S.B., Raber-Durlacher, J.E. et al. Clinical approach in the management of oral chronic graft-versus-host disease (cGVHD) in a series of specialized medical centers. *Support Care Cancer* 23, 1615–1622 (2015). <https://doi.org/10.1007/s00520-014-2503-x>
12. Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy [published correction appears in *Cancer*. 2015 Apr 15;121(8):1339]. *Cancer*. 2014;120(10):1453-1461. doi:10.1002/cncr.28592

Disclaimer

Any person seeking to apply or consult the guide for practice document, is expected to use independent clinical judgement in the context of individual clinical circumstances, or seek out the supervision of a qualified specialist clinician. Ontario Health makes no representation or warranties of any kind whatsoever regarding their content, use, or application, and disclaims responsibility for their application or use in any way.

Acknowledgements

A wide variety of health professionals were invited to participate in the development of this algorithm, as well as in the external review. Every effort was made to ensure as broad a professional and regional representation as possible.

Dr. Saunders BSc, DMD

Health Sciences North Sudbury
(Oral Care Group Lead)

Colleen Bedford, BSc

Ontario Health

Alaa El-Danab, MSc.A, RD

Princess Margaret Cancer Centre

Alexandra Fleury-Catterall, M.Sc.S, Speech-Language Pathologist, Reg. CASLPO

Health Sciences North Sudbury

Anahita Djalilvand, RD, MScFN

Lakeridge Health

Andrea Gomes, BSc, MCISc, S-LP (C), Reg. CASLPO

University Health Network

Callie Gross, RD

Health Sciences North Sudbury

Casey Kouvelas, MN, RN

Clinical Practice Manager, Windsor Regional Cancer Centre

Regional Oncology Nursing Lead, Erie St. Clair Regional Cancer Program

Dr. Erin Watson, DMD, MHSc

Deputy Chief of Dentistry
Princess Margaret Cancer Centre

Karen Biggs, RD

Juravinski Hospital and Cancer Centre

Lia Kutzscher, NP

London Health Sciences Centre

Linda Hamelin NP-Adult, MN

The Ottawa Hospital

Melissa Touw, Clinical Nurse Specialist

Kingston General Hospital

Dr. Mireille Kaprilian, HBSc, DDS

Clinical Associate Dentist
Princess Margaret Cancer Centre

Nicole Chenier-Hogan RN(EC), BA, BNSc, MSc, CNN(c)

Nurse Practitioner; Radiation Oncology
Cancer Centre Southeastern Ontario/Kingston Health Sciences Centre

Olivia Lemenchick, RN

London Health Sciences Centre

Rita Valvasori, Registered Dental Hygienist

Rosemary Rivera, Professional Practice Leader
Markham Stouffville Hospital

Wilf Steer BScPhm MBA

Outpatient Oncology Pharmacist
Health Sciences North Sudbury